Organigram Holdings Stock Earnings Reports

Organigram reported a record quarter driven by a full quarter contribution from the Motif acquisition and organic growth, with net revenue of $65.6M (up 74% YoY) and gross sales exceeding $100M (up 79% YoY). The company is strengthening its leadership in Canada (notably #1 LP share in vapes and pre-rolls) while accelerating international expansion — increased exports (Germany, UK, Australia), an upcoming EU‑GMP certification, and the consolidation of US hemp‑derived THC beverage revenue following the Collective Project acquisition. Operational investments include expanded extraction capacity, a $9M LED upgrade and additional Moncton capacity (total ~14,000 kg annual uplift), $1.2M beverage line in Winnipeg, and further Motif integration; management now expects annual synergies of ~$15M next year (up from $10M prior). Financially, adjusted gross margin was 33% (Organigram standalone ~37%), adjusted EBITDA was $4.9M (positive), and the company ended the quarter with ~$83.4M cash and negligible debt; guidance calls for adjusted gross margin to stabilize around 35% in fiscal 2025 with a long‑term target of ~40% in H2 fiscal 2026, and the expectation of being cash‑flow positive for the year. Key investor considerations: meaningful near‑term upside from international sales and Motif synergies, continued investment to support US beverage rollout, capacity expansion to capture tightening Canadian supply, and one‑time/non‑cash impacts (derivative fair‑value movement) that materially affected net income this quarter.